Integra LifeSciences (NASDAQ:IART) Price Target Cut to $12.00 by Analysts at Truist Financial

Integra LifeSciences (NASDAQ:IART) had its target price decreased by equities researchers at Truist Financial from $13.00 to $12.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “hold” rating on the life sciences company’s stock. Truist Financial’s price target points to a potential upside of 7.05% from the stock’s current price.

Several other research analysts have also recently issued reports on the company. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday. Citigroup cut their target price on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research report on Wednesday, March 11th. Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Wells Fargo & Company raised Integra LifeSciences to a “hold” rating in a research report on Wednesday, March 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Integra LifeSciences currently has an average rating of “Reduce” and an average target price of $14.20.

Integra LifeSciences Stock Up 1.4%

Shares of NASDAQ IART traded up $0.15 during midday trading on Wednesday, hitting $11.21. 131,776 shares of the stock traded hands, compared to its average volume of 770,243. The company has a market cap of $873.71 million, a PE ratio of -1.67 and a beta of 1.06. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. Integra LifeSciences has a one year low of $8.70 and a one year high of $17.54. The business has a 50 day moving average price of $10.23 and a two-hundred day moving average price of $12.03.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04. The company had revenue of $434.93 million for the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.Integra LifeSciences’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, equities analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Several hedge funds have recently made changes to their positions in IART. Rubric Capital Management LP raised its stake in shares of Integra LifeSciences by 58.4% in the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after buying an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY raised its stake in shares of Integra LifeSciences by 57.5% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock valued at $26,767,000 after buying an additional 796,300 shares during the period. Invenomic Capital Management LP raised its stake in shares of Integra LifeSciences by 78.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock valued at $13,115,000 after buying an additional 463,729 shares during the period. Kotler Kevin bought a new stake in shares of Integra LifeSciences in the fourth quarter valued at $5,309,000. Finally, SG Americas Securities LLC bought a new stake in shares of Integra LifeSciences in the fourth quarter valued at $4,722,000. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.